Abstract
Interleukin-2 (IL-2) controls the function of regulatory T cells (Treg) and defects in the IL-2 pathway contribute to multiple autoimmune diseases. Although IL-2 therapy has been efficacious in certain inflammatory conditions, the capacity for IL-2 to also activate inflammatory effector responses highlights the need for IL-2-based therapeutics with improved Treg-specificity. We 5 targeted conserved residues in IL-2 that mediate receptor binding, and identified an optimal IL-2 mutein with reduced potency, but enhanced Treg selectivity due to increased dependence on the IL-2-receptor component CD25. IL-2 mutein treatment led to selective Treg enrichment and reduced agonism of effector cells across a wide dose range, resulting in sustained resolution of spontaneous autoimmunity. Thus, this IL-2 mutein allows for safe and targeted control of the 10 autoimmune response.
One Sentence Summary
A CD25-dependent IL-2 mutein selectively expands regulatory T cells and provides safe and effective control of autoimmunity.
Main Text
Regulatory T cells (Tregs) maintain immune homeostasis and prevent autoimmunity (1, 2) . Tregs rely on interleukin 2 (IL-2) for their maintenance and function (3) , and boosting IL-2 activity has been explored for treatment of autoimmunity. The IL-2 receptor (IL-2R) is expressed either as an intermediate-affinity dimer, composed of IL-2Rb (CD122) and the common cytokine receptor 5 gamma chain (CD132), or a high-affinity trimer that includes CD25, which has no signaling capacity but functions by binding IL-2 and presenting it to the CD122/CD132 signaling complex (4). CD25 is constitutively expressed by most Foxp3 + regulatory T cells (Tregs) (5-7), making them highly responsive to limiting amounts of IL-2. CD25 is also induced on conventional CD4 + and CD8 + T cells after TCR stimulation, and CD122/CD132 are highly expressed on memory 10 CD8 + T cells and NK cells (8). To avoid activation of these effector cells, IL-2 has been tested at the lowest biologically active doses in autoimmune patients (9) . Nevertheless, balancing the efficacy and the safety of IL-2 therapy remains a major concern, and thus there is a pressing need for IL-2 based therapeutics with improved Treg-selectivity.
We hypothesized that reducing IL-2 binding to CD122 would increase CD25 dependency, and 15 thereby improve Treg-selectivity in therapeutic settings. For this, we generated constructs for twenty-eight mouse IL-2 variants (IL-2 muteins, table S1), mutating conserved residues with known functional importance at the CD122 contact interface (10) . To improve pharmacokinetics and tissue distribution, the IL-2 muteins were fused to a mutated IgG2a Fc domain with abolished effector function (hereafter referred to as Fc.WT and Fc.muteins). We expressed the constructs in 20 and Fc.Mut12) to weak (Fc.Mut25 and Fc.Mut26) activity for further evaluation. When titrated on freshly isolated splenocytes, Fc.Mut24, Fc.Mut12 and Fc.Mut25 showed reduced signaling activity on Treg cells that was highly CD25-dependent, but unlike Fc.WT did not stimulate 5 CD4 + Foxp3 -T cells, CD8 + T cells or NK cells even at high doses ( Fig. 1 , A-C). We confirmed with CD25-expressing HEK cells that the Fc.muteins bound CD25 with the same affinity as Fc.WT ( fig. S2 ), establishing that reduced signaling potency was due to impaired interaction with CD122 or CD122/CD132 heterodimers. To assess the Treg selectivity of the Fc.muteins under conditions more closely resembling inflamed tissues, we used splenocytes that were pre-activated with anti-10 CD3, which results in elevated CD25 expression and enhanced IL-2 responsiveness of both CD4 + Foxp3and CD8 + T cells. Again, we found that the Fc.muteins were more Treg-selective than Fc.WT across a wide dose range ( fig. S3A ), and that decreasing potency of the Fc.muteins correlated with enhanced dependence on CD25 for signaling ( fig. S3B ).
To extend these findings in vivo, we compared responses of IL-2 sensitive lymphocytes in the 15 lymph nodes of B6 mice after treatment with Fc.WT, Fc.Mut12, Fc.Mut24 and Fc.Mut25.
Interestingly, despite its weaker activity in vitro, Fc.Mut24 was even more effective than Fc.WT at expanding the Treg population in vivo, whereas Fc.Mut12 showed weaker activity and Fc.Mut25 had no effect (Fig. 1 , D and E). Additionally, Fc.Mut24 showed the greatest degree of Treg expansion vs. effector CD8 + T cells and NK cells (Fig. 1 , F and G), and based on these results we 20
selected Fc.Mut24 as the optimal candidate for Treg-enrichment based therapy.
We compared the kinetics of in vivo responses in Treg cells to Fc.WT and Fc.Mut24 by examining Tregs cells in the blood between 3-7 days following a single treatment. In Fc.WT-treated mice, the percentage of Tregs in the blood peaked on day 3 and declined rapidly to near baseline by day 7.
By contrast, the response to Fc.Mut24 peaked at day 4, then slowly declined but remained elevated compared to baseline for at least a week (Fig. 2, A and B ). Furthermore, at all timepoints the ratios of Treg:CD8 + cell and Treg:NK cell were higher in Fc.Mut24-treated mice than in Fc.WT-treated ones, indicating that Treg-selectivity is maintained throughout the response (Fig. 2 , C and D). The narrow dose-range that must be used to avoid effector cell activation is a barrier to the implementation of IL-2-based therapies in autoimmune diseases. To determine if the increased 20 CD25-dependency of Fc.Mut24 would enable a wider-dose range while maintaining Tregselectivity, we assessed Treg and effector lymphocyte activation in response to increasing doses of Fc.WT or Fc.Mut24. As indicated by induction of the proliferation marker Ki-67, both Fc.WT and Fc.Mut24 activated Tregs in a dose-dependent manner. However, whereas Fc.WT also activated CD4 + Foxp3 -T cells, CD8 + T cells and NK cells, Fc.Mut24 showed only low activity in NK cells at the highest doses tested (Fig. 3A) . Consequently, there was a robust dose-dependent increase in the frequency of Tregs compared to the effector populations in Fc.Mut24-treated animals, with Tregs reaching more than 50% of CD4 + T cells at the highest dose. In contrast, the 5
Treg response to Fc.WT plateaued at less than 30% Treg (Fig. 3, B to E). Stimulation of NK cells by Fc.Mut24 in vivo is curious given their lack of CD25 expression and the inability of Fc.Mut24 to stimulate NK cells in vitro. However, NK cells express extremely high levels of CD122, and trans-presentation of IL-2 by CD25-expressing cells to CD122 hi cells has been reported (11). Thus, this NK response may represent the limit of Treg specificity that can be achieved by selectively 10 targeting IL-2 to CD25 + cells.
To determine if the Treg-selectivity of Fc.Mut24 is maintained at sites of ongoing autoimmunity, we treated 9-week old female non-obese diabetic (NOD) mice with a single 15µg dose of Fc.WT, Fc.Mut24, or PBS, and assessed responses of different lymphocyte populations in the spleen, pancreatic lymph node and pancreas. In the NOD model of type 1 diabetes (T1D), autoimmunity 15 begins as early as 3 weeks of age (12) , and is characterized by infiltration of CD25 + effector T cells in the pancreas (13) . Indeed, both CD4 + Foxp3and CD8 + T cells in the pancreas, but not the pancreatic lymph node, of NOD mice upregulated Ki-67 in response to high-dose Fc.Mut24 ( fig.   S4 ). However, despite this apparent loss of Treg-selectivity in an IL-2R-proximal response, we still observed dominant expansion of Tregs in all tissues of Fc.Mut24-treated NOD mice that was 20 superior to that in Fc.WT-treated animals (Fig. 4, A to D) .
In the NOD T1D model, low-dose IL-2 treatment led to significant disease protection, whereas, high-dose IL-2 treatment actually accelerated disease (13) . Thus, this model should allow us to determine if the improved Treg-selectivity and pharmacokinetics of Fc.Mut24 would translate to better therapeutic efficacy across a wider dose-range and with reduced dosing frequency.
Beginning at 10 weeks of age, we treated NOD mice with either a low (3µg) or high (15µg) dose of Fc.WT or Fc.Mut24 for a total of 5 doses over 18 weeks, and monitored blood glucose levels until 34 weeks of age. By 25 weeks, all control mice developed diabetes. In contrast, low-dose 5
Fc.Mut24 treatment offered substantial disease protection that was comparable to that observed in Fc.WT-treated mice. However, whereas the efficacy of high-dose Fc.WT was somewhat reduced, high-dose Fc.Mut24 further enhanced protection against diabetes, with 75% of the mice remaining disease-free ( Fig. 4E ). Consistent with our in vitro and in vivo Fc.mutein characterization, this indicates that Fc.Mut24 is immunosuppressive across a wide dose range compared to Fc.WT. 10
To further evaluate the therapeutic efficacy of Fc.Mut24, we compared Fc.WT and Fc.Mut24 in the NOD model using a dose escalation regimen in which mice were given a single low-dose (3µg) of Fc.WT or Fc.Mut24, followed 4 days later by a 12 week course of bi-weekly high-dose (15µg), a strategy that would still allow Treg to return to baseline frequencies between doses (Fig. 2) .
Indeed, consistent with previous studies, this high-dose/bi-weekly Fc.WT treatment significantly 15 accelerated disease development compared to PBS-treated controls. In contrast, Fc.Mut24 conferred a significant and durable protection against diabetes lasting for at least 20 weeks following treatment cessation (Fig. 4F) . Importantly, histological examination of the mice that were diabetes-free at the end of the study showed a dramatic reduction in the severity of insulitis in the Fc.Mut24-treated mice compared to PBS controls (Fig.4, G and H) . Taken together, these 20 results reveal the capacity for transient, periodic Treg enrichment with Fc.Mut24 to maintain efficient and targeted control of autoimmunity, despite the presence of Fc.mutein-responsive pathogenic T cells at the site of autoimmune inflammation.
A recent clinical trial investigating the effects of low-dose IL-2 (LD IL-2) therapy across 11 autoimmune diseases has shown encouraging signs of efficacy using a dose of 1 MIU/injection in all patients (14) . However, finding a "universal" dosage in autoimmunity is very challenging. In addition to the heterogeneity observed in the physiopathology of autoimmune diseases, some patients may also carry intrinsic alterations of the IL-2 pathway (15) that can limit the efficacy of 5 the treatment, as in T1D (16) . Our results demonstrate that increased CD25-dependency of Fc.muteins translates into an improved dynamic range of selective Treg enrichment and a greater flexibility in dosing strategies, without compromising efficacy or safety. Furthermore, due to prolonged immune modulation following individual doses, we found that chronic Treg enrichment was not required to provide lasting protection against predisposed autoimmunity. Recently, human 10 IL-2 muteins have been described with similar Treg selective properties in vitro and in the clinic (17) (18) (19) , and our findings provide a strong proof-of-concept for IL-2 mutein therapy. Indeed, through optimal and targeted control of the autoimmune response, this approach represents a more efficient and safer alternative to LD IL-2. 
